Big difference. I think that because we’ve been doing the BPC+TB500 stack almost every day for 20 months, with several 1 week breaks, we are primed to heal.
I’ve posted on this before, I recover from hard work overnight.
I have several gym rats, including our 41 y/o son who also experiences rapid recovery and healing and misses that benefit when we have an off week. He has gained about 8lbs of muscle since this photo and lost 5lbs of fat. He’s around 185lb. All while on a weekly dose of 1.5mg Reta
I have not tried GHK-cu as an injectable but I’ve been making a skin care product with that peptide for over 3 years and have a lot of local repeat customers. It works!!
I do take other peptides that support mitochondria.
This thread has a lot more info on a wider range of peptides.
We established a theoretical model for how the modulation of GLP-1 agonists via increased serotonergic activity at the 5-HT2C receptor may have an associated negative effect on sexual desire. We then applied a biopsychosocial framework to highlight why this effect may be overlooked by both GLP-1-treated patients and clinicians. Although the serotonergic pathway may create a physiological decrease in sexual desire for patients taking GLP-1 agonists, the biopsychosocial factors discussed propose a potential mechanism by which these adverse effects are masked. In other words, we postulate that the negative influence of GLP-1 agonism on sexual desire, mediated by serotonergic pathways, as well as undesirable facial effects (“Ozempic Face”) and increased SHBG, etc., are offset by the positive influences on sexual desire such as increased total testosterone, improved vascular reactivity, and a more positive mood.
Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group
Old semaglutide still has some tricks up its sleeves
